Zytiga, the brand name for abiraterone acetate, has revolutionized the treatment of metastatic castration-resistant prostate cancer. This article delves into its efficacy, usage, and the benefits it offers to patients.
What is Zytiga?
Zytiga is an androgen biosynthesis inhibitor used to treat prostate cancer. It specifically targets and inhibits CYP17, an enzyme critical in androgen production, thus reducing testosterone levels that promote cancer growth.
Mechanism of Action
Zytiga works by blocking CYP17, leading to a significant decrease in androgen production from the adrenal glands, testes, and prostate tumour tissues. This hormonal suppression helps control the progression of prostate cancer.
Clinical Uses
Metastatic Prostate Cancer: Zytiga is used in combination with prednisone to manage mCRPC in patients who have progressed despite androgen deprivation therapy.
Pre-Chemotherapy: It is also beneficial for patients who have not yet received chemotherapy, providing a treatment option that delays the need for more aggressive therapies.
Dosage Information
The standard dosage is 500mg taken once daily on an empty stomach, along with 500 mg of prednisone twice daily. Adherence to this regimen is crucial for optimal results.
Potential Side Effects
Patients may experience side effects such as hypertension, hypokalemia, and liver function abnormalities. Regular monitoring and supportive care are essential to manage these adverse effects.
Zytiga Price
In India, Zytiga is available at competitive prices through Chawla Medicos, ensuring that patients can access this life-saving medication without prohibitive costs.
Conclusion
Zytiga plays a crucial role in the management of advanced prostate cancer. Its ability to significantly reduce androgen levels makes it a cornerstone in the treatment of mCRPC. For cost-effective access to Zytiga, Chawla Medicos stands out as a reliable supplier.
Sign in to leave a comment.